JP2023528017A5 - - Google Patents
Info
- Publication number
- JP2023528017A5 JP2023528017A5 JP2022573138A JP2022573138A JP2023528017A5 JP 2023528017 A5 JP2023528017 A5 JP 2023528017A5 JP 2022573138 A JP2022573138 A JP 2022573138A JP 2022573138 A JP2022573138 A JP 2022573138A JP 2023528017 A5 JP2023528017 A5 JP 2023528017A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279763A JP2026062799A (ja) | 2020-05-26 | 2025-12-24 | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305550 | 2020-05-26 | ||
| EP20305550.4 | 2020-05-26 | ||
| EP20306415 | 2020-11-20 | ||
| EP20306415.9 | 2020-11-20 | ||
| EP21305092.5 | 2021-01-26 | ||
| EP21305092 | 2021-01-26 | ||
| EP21305482 | 2021-04-12 | ||
| EP21305482.8 | 2021-04-12 | ||
| PCT/EP2021/064098 WO2021239838A2 (en) | 2020-05-26 | 2021-05-26 | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279763A Division JP2026062799A (ja) | 2020-05-26 | 2025-12-24 | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528017A JP2023528017A (ja) | 2023-07-03 |
| JP2023528017A5 true JP2023528017A5 (enExample) | 2024-06-17 |
Family
ID=76159441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573138A Pending JP2023528017A (ja) | 2020-05-26 | 2021-05-26 | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
| JP2025279763A Pending JP2026062799A (ja) | 2020-05-26 | 2025-12-24 | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279763A Pending JP2026062799A (ja) | 2020-05-26 | 2025-12-24 | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230212231A1 (enExample) |
| EP (1) | EP4157343A2 (enExample) |
| JP (2) | JP2023528017A (enExample) |
| KR (1) | KR20230042222A (enExample) |
| BR (1) | BR112022024063A2 (enExample) |
| CA (1) | CA3184802A1 (enExample) |
| CO (1) | CO2022018389A2 (enExample) |
| MX (1) | MX2022014943A (enExample) |
| WO (1) | WO2021239838A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102770457A (zh) * | 2009-03-10 | 2012-11-07 | 贝勒研究院 | 靶向抗原呈递细胞的疫苗 |
| EP4157344A2 (en) * | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| WO2023088968A1 (en) * | 2021-11-17 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Universal sarbecovirus vaccines |
| CN114807179B (zh) * | 2022-06-01 | 2022-10-21 | 广州达博生物制品有限公司 | 一种新型冠状病毒肺炎疫苗的构建与应用 |
| KR20250017151A (ko) * | 2023-07-21 | 2025-02-04 | 세종대학교산학협력단 | 항 cd98 단일클론항체 및 이의 용도 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN100588430C (zh) * | 2004-02-20 | 2010-02-10 | 复旦大学 | 基于表位的SARS-Cov基因疫苗及其构建 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CN101657464A (zh) | 2007-02-02 | 2010-02-24 | 贝勒研究院 | 与靶向人源化单克隆抗体复合的多变量抗原 |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| ES2685823T3 (es) | 2008-07-16 | 2018-10-11 | Baylor Research Institute | Anticuerpos antagonistas anti-CD40 |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| DK2406289T3 (en) | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| EP2477655A4 (en) | 2009-09-14 | 2014-02-12 | Baylor Res Inst | VACCINES TREATED ON LANGERHANS CELLS |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| KR20130108295A (ko) | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2014085580A1 (en) * | 2012-11-28 | 2014-06-05 | Baylor Research Institute | Methods and compositions involving a flu vaccine |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| EA029661B1 (ru) | 2013-09-06 | 2018-04-30 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов |
| US10849972B2 (en) * | 2018-11-27 | 2020-12-01 | King Adulaziz University | Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus |
| IT202000009625A1 (it) * | 2020-04-30 | 2021-10-30 | Takis S R L | Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini. |
-
2021
- 2021-05-26 MX MX2022014943A patent/MX2022014943A/es unknown
- 2021-05-26 CA CA3184802A patent/CA3184802A1/en active Pending
- 2021-05-26 WO PCT/EP2021/064098 patent/WO2021239838A2/en not_active Ceased
- 2021-05-26 JP JP2022573138A patent/JP2023528017A/ja active Pending
- 2021-05-26 BR BR112022024063A patent/BR112022024063A2/pt unknown
- 2021-05-26 EP EP21728243.3A patent/EP4157343A2/en active Pending
- 2021-05-26 KR KR1020227045248A patent/KR20230042222A/ko active Pending
- 2021-05-26 US US17/927,804 patent/US20230212231A1/en active Pending
-
2022
- 2022-12-19 CO CONC2022/0018389A patent/CO2022018389A2/es unknown
-
2025
- 2025-12-24 JP JP2025279763A patent/JP2026062799A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023528017A5 (enExample) | ||
| US20230303718A1 (en) | Modified Antibody | |
| US20210221904A1 (en) | Fusion proteins comprising an anti-cd40 antibody and hiv antigenic peptides | |
| CA2754743C (en) | Antigen presenting cell targeted anti-viral vaccines | |
| JP5363432B2 (ja) | 樹状細胞−ｔ細胞の相互作用を調節するための組成物及び方法 | |
| EP2406286B1 (en) | Anti-cd40 antibodies and uses thereof | |
| Borrebaeck | Strategy for the production of human monoclonal antibodies using in vitro activated B cells | |
| TWI423985B (zh) | 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用 | |
| TW200902061A (en) | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | |
| CN1423700A (zh) | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 | |
| KR20130036246A (ko) | 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍 | |
| JP2010518024A (ja) | 樹状細胞アシアロ糖タンパク質受容体（ｄｃ−ａｓｇｐｒ）を介して抗原提示細胞に結合する作用物質 | |
| KR20090127886A (ko) | 수지상 세포 렉틴 유사 산화된 ｌｄｌ 수용체-1(ｌｏｘ-1)을 통한 사람 항원제시세포의 활성화 | |
| JP2023554587A5 (enExample) | ||
| WO1998033523A1 (en) | Vaccination methods and molecules | |
| CN103044552A (zh) | 人源化的抗树突状细胞表面dec-205分子的单克隆抗体 | |
| HK1153501A (en) | Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr) | |
| Lee et al. | Expression of a Functional Single-Chain | |
| HK1227905A1 (en) | Antigen presenting cell targeted vaccines | |
| HK1178546A (en) | Antigen presenting cell targeted vaccines | |
| HK1191026A (en) | Antigen presenting cell targeted cancer vaccines |